Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert S Svatek

Showing results (1-10 of 178) with videos related to

Pageof 18
Sort By:
The Journal of Urology|March 17, 2018
Editorial CommentRobert S Svatek
European Urology|April 20, 2015
Long-term outcomes of the FinnBladder-4 studyRobert S Svatek
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Cost-effectiveness of bladder cancer screeningYair Lotan, Robert S Svatek
Cancer Prevention Research (Philadelphia, Pa.)|December 18, 2010
Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigenRobert S Svatek, Yair Lotan
Current Urology Reports|August 16, 2008
Is there a rationale for bladder cancer screening?Robert S Svatek, Yair Lotan
European Urology|May 24, 2008
Editorial comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsyShahrokh F Shariat, Robert S Svatek
European Urology|December 10, 2009
Words of wisdom. Re: Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. Lotan Y, Shariat SF; NMP22 Study Group. BJU Int 2008;101:1362-7Robert S Svatek, Colin P Dinney
The Urologic Clinics of North America|April 18, 2015
Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancerBrock E Boehm, Robert S Svatek
European Urology|April 4, 2012
Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusWilliam M Hilton, Robert S Svatek
Urology|April 12, 2011
Editorial commentRobert S Svatek, Dipen J Parekh
Pageof 18

Showing results (1-10 of 178) with videos related to

Sort By:
Pageof 18
The Journal of Urology|March 17, 2018
Editorial CommentRobert S Svatek
European Urology|April 20, 2015
Long-term outcomes of the FinnBladder-4 studyRobert S Svatek
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Cost-effectiveness of bladder cancer screeningYair Lotan, Robert S Svatek
Cancer Prevention Research (Philadelphia, Pa.)|December 18, 2010
Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigenRobert S Svatek, Yair Lotan
Current Urology Reports|August 16, 2008
Is there a rationale for bladder cancer screening?Robert S Svatek, Yair Lotan
European Urology|May 24, 2008
Editorial comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsyShahrokh F Shariat, Robert S Svatek
European Urology|December 10, 2009
Words of wisdom. Re: Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. Lotan Y, Shariat SF; NMP22 Study Group. BJU Int 2008;101:1362-7Robert S Svatek, Colin P Dinney
The Urologic Clinics of North America|April 18, 2015
Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancerBrock E Boehm, Robert S Svatek
European Urology|April 4, 2012
Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusWilliam M Hilton, Robert S Svatek
Urology|April 12, 2011
Editorial commentRobert S Svatek, Dipen J Parekh
Pageof 18